Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07194395 · ClinicalTrials.gov registry record

Contactless Optical Monitoring of AV Access Using the PatenSee System in Outpatient Hemodialysis Patients

A clinical trial of Hemodialysis and Clinical Assessment, sponsored by PatenSee.

Recruiting
Registry status
90
Enrollment target
2
Study locations

NCT07194395: Recruiting study of Hemodialysis and Clinical Assessment, sponsored by PatenSee.

NCT07194395 is a study of Hemodialysis and Clinical Assessment that is actively recruiting participants, run by PatenSee. The registered enrollment target is 90 participants, below the 131-participant average among 12 other Hemodialysis trials with a reported enrollment target (31% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07194395, a study of Hemodialysis and Clinical Assessment, is actively recruiting participants, sponsored by PatenSee.

RECRUITING
Registry status
90 participants
Enrollment target
2
Study locations

Study Summary

This is a prospective, non-interventional, single arm, international multicenter study in which up to 120 adult participants with kidney failure requiring regular hemodialysis through arteriovenous (AV) access (AV fistula or graft) will be recruited and evaluated using the PatenSee system. Data captured on the PatenSee system will be analyzed and evaluated against standard of care clinical monitoring of AV accesses.

Primary Outcome

Agreement between the ability to detect AV access structure parameters by PatenSee's images and the ability to detect the same parameters by clinical monitoring

Interventions

  • DEVICE PatenSee System

Study Locations (2)

Michigan

  • Henry Ford Hospital - Detroit

Hasharon

  • Meir Medical Center - Kfar Saba

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2025-06-06
Est. Completion 2027-02-28
PatenSee

1 total trials

What NCT07194395 shows while recruiting

NCT07194395 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 131-participant average among 12 other Hemodialysis trials with a reported enrollment target (31% lower).

The record links to 2 conditions, with Hemodialysis appearing as the primary indexed condition, and to 1 intervention - of which PatenSee System is the first listed.

NCT07194395 reports a single indexed study location in Michigan, Hasharon.

Frequently Asked Questions

What is clinical trial NCT07194395 about?

NCT07194395 is a clinical study titled "Contactless Optical Monitoring of AV Access Using the PatenSee System in Outpatient Hemodialysis Patients". This is a prospective, non-interventional, single arm, international multicenter study in which up to 120 adult participants with kidney failure requiring regular hemodialysis through arteriovenous (AV) access (AV fistula or graft) will be recruited and evaluated using the PatenSee system. Data cap...

What is the current status of trial NCT07194395?

This trial is currently recruiting. The enrollment target is 90 participants. The study started on 2025-06-06. Estimated completion is 2027-02-28.

What conditions does trial NCT07194395 study?

This clinical trial studies the following conditions: Hemodialysis, Clinical Assessment.

What interventions are being tested in trial NCT07194395?

The interventions under investigation include: PatenSee System (DEVICE).

Who is sponsoring clinical trial NCT07194395?

This trial is sponsored by PatenSee, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07194395 being conducted?

This trial has 2 study locations across Michigan, Hasharon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hemodialysis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07194395's enrollment target sits among peer trials

90 6th of 12 higher than 7 of 12 other Hemodialysis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hemodialysis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02521311 · 90 participants · Phase 2

    Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)

  • NCT02939573 · 90 participants · Phase 2

    A Randomized Multicenter Study for Isolated Skin Vasculitis

  • NCT03128879 · 90 participants · Phase 2

    Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

  • NCT03184038 · 90 participants · NA

    Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07194395, the US trial registry maintained by the National Library of Medicine. NCT07194395 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.